# clinical - LLM run 003

- Script: `llm-test/clinical-llm.py`
- Exit code: `0`

## Terminal Output

```text
No cooldown configured for this backend.

======================================================================
ANSWER
======================================================================
Backend: openai
Model:   qwen2.5:7b
```python
context = """
CLINICAL TRIAL DOCUMENT:

TRIAL ARCHIVE DOCUMENT

[NOISE BLOCK 1 — random filler]
The site coordination team completed re-training on GCP guidelines in October.
All monitors completed their annual certification before the Q4 site visits.
The IRB submission for the Phase II extension was approved with minor revisions.
Data lock for the primary endpoint analysis is scheduled for the end of March.
[...][SNIP]...[...]

[TARGET FACT — buried segment]
PATIENT RECORD: Subject ID PT-2247
Site: Site 03 | Enroll date: 2024-09-02
Assigned drug: Compound VX-7 (high dose, 80mg)
Allergy flag: PCN-HIGH
Baseline creatinine: 1.34 mg/dL
Last visit: Week 16 | Status: Active
Treating physician: Dr. Anika Rao
Note: Subject PT-2247 is flagged for enhanced renal monitoring due to
creatinine trending above threshold at Week 12 visit (1.61 mg/dL).

[NOISE BLOCK 3 — random filler]
The supply chain team confirmed that drug kits for the final cohort were
shipped to Sites 01, 02, and 05 on January 6th. Cold chain compliance was
verified for all shipments. Site 03 requested an additional 30-day supply
owing to a higher-than-expected screen pass rate. The IRT system was updated
to reflect new randomization blocks effective January 10th. An unblinding
SOP was reviewed and signed off by the sponsor medical officer.
The trial master file index was audited and found to be 98% complete.
Two documents were flagged for re-filing.

[NOISE BLOCK 4 — misleading fact]
Note: An earlier data entry for PT-2247 recorded the allergy flag as
PENICILLIN-MODERATE, entered in error by site staff on 2024-09-04.
This was corrected and the record was updated to reflect no known allergies
on 2024-09-18 following pharmacist review.

[NOISE BLOCK 5 — random filler]
The Phase I safety review committee met on December 3rd to evaluate the
dose-escalation findings. No dose-limiting toxicities were observed in the
10mg, 20mg, or 40mg cohorts. The 80mg cohort review is ongoing. Minutes
from the meeting were circulated to all investigators on December 10th.
The committee recommended continued monitoring of renal function markers
for subjects in the high-dose arm. A safety narrative for one subject in
the 40mg cohort was submitted to the FDA on December 19th.

[NOISE BLOCK 6 — similar entity decoy]
PATIENT RECORD: Subject ID PT-2274
Site: Site 05 | Enroll date: 2024-09-11
Assigned drug: Compound VX-7 (high dose, 80mg)
Allergy flag: NONE
Baseline creatinine: 1.02 mg/dL
Last visit: Week 16 | Status: Withdrawn (subject request)

[NOISE BLOCK 8 — similar entity decoy]
PATIENT RECORD: Subject ID PT-2247-SCREEN
Site: Site 03 | Screen date: 2024-08-28
Status: Screen pass — enrolled as PT-2247
Allergy flag recorded at screening: NONE
Baseline creatinine at screening: 1.29 mg/dL
Note: Pre-enrollment screening record only. Superseded by enrollment record.
"""

question = """
Q1 [Single-hop retrieval]:
What is the allergy flag currently recorded for subject PT-2247?
Answer with the exact flag value only.

Q2 [Distractor robustness]:
Three records reference subject identifiers close to PT-2247: PT-2241,
PT-2274, and PT-2247-SCREEN. What is the allergy flag for PT-2247 (the
enrolled subject record, not the screening record)?
Answer with the exact flag value only.

Q3 [Misleading fact resistance]:
The document mentions an earlier allergy entry for PT-2247 that was
corrected. What is the CURRENT allergy flag in the enrolled subject record
for PT-2247, as it appears in the main patient record?
Answer with the exact flag value only.

Q4 [Span extraction]:
Copy the exact sentence from the document that explains why PT-2247 is
flagged for enhanced renal monitoring.

Q5 [Multi-hop reasoning]:
Using only information present in this document:
- What drug and dose is PT-2247 receiving?
- What did the Phase I safety review committee recommend for subjects in
  that dose cohort?
Combine these two facts to explain what ongoing protocol action should
apply to PT-2247. Show your reasoning step by step.
"""

final_answer = """
Q1: PCN-HIGH
Q2: PCN-HIGH
Q3: PCN-HIGH
Q4: Subject PT-2247 is flagged for enhanced renal monitoring due to creatinine trending above threshold at Week 12 visit (1.61 mg/dL).
Q5: Step-by-step reasoning:
- PT-2247 is receiving Compound VX-7 at a high dose of 80mg.
- The Phase I safety review committee recommended continued monitoring of renal function markers for subjects in the high-dose arm.
Therefore, enhanced renal monitoring should continue for PT-2247.
"""

print(final_answer)
```

======================================================================
LATENCY BREAKDOWN
======================================================================
  Total wall time:    112.244s

======================================================================
TOKEN USAGE
======================================================================
qwen2.5:7b: input=1,645, output=1,234, calls=1
======================================================================
```
